Evidence map›Paper›PMID 40638072›Full record

ArticleJournal of virology2025

The HCMV tegument protein UL88 degrades MyD88 and reduces innate immune activation.

Rinki Kumar, Irene E Reider, Madison Martin, Julia S Simpson, Nicholas J Buchkovich, Christopher C Norbury

Abstract read
In one paragraph

Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Rinki KumarDepartment of Cell and Biological Systems, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania, USA.
Irene E ReiderDepartment of Cell and Biological Systems, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania, USA.
Madison MartinDepartment of Cell and Biological Systems, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania, USA.
Julia S SimpsonDepartment of Cell and Biological Systems, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania, USA.
Nicholas J BuchkovichDepartment of Cell and Biological Systems, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania, USA.
Christopher C NorburyDepartment of Cell and Biological Systems, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania, USA.ORCID 0000-0001-7411-6987

Funding

Analysis of the mechanism of HCMV cytoplasmic envelopmentR01AI130156 · NIAID · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI Christopher C Norbury · 2017 to 2026
$3.8M
How does Cytomegalovirus use interferon lambda for optimal spreadR21AI169180 · NIAID · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI NORBURY, CHRISTOPHER C · 2022 to 2023
$446k
The effect of local virus infection upon cutaneous wound healing: the impact of virus-induced Type III IFNsR21AR077778 · NIAMS · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI NORBURY, CHRISTOPHER C · 2021 to 2022
$390k
National Institute of Allergy and Infectious Diseases AI130156National Institute of Allergy and Infectious Diseases AI169180NIAID NIH HHS R01 AI130156NIAID NIH HHS R21 AI169180NIAMS NIH HHS AR077778NIAMS NIH HHS R21 AR077778
6 · The paper itself

Abstract

The human cytomegalovirus (HCMV) encodes the tegument protein UL88, which supports virus spread by mediating the degradation of the innate immune signaling adapter protein, myeloid differentiation primary response 88 (MyD88). MyD88 transduces signals in multiple innate immune pathways, including acting downstream of pattern recognition receptors and IL-1 cytokine family members. MyD88 is rapidly and robustly upregulated following exposure to HCMV, irrespective of viral gene expression and, even after infection, primarily within uninfected cells in a culture. However, UL88 was required to downregulate cellular MyD88 protein levels as HCMV spread through a culture. The N-terminal 181 amino acids of UL88 were required to associate with and downregulate MyD88 protein. MyD88 expression significantly suppressed virus spread by triggering the production of a heat-labile soluble factor. This factor was produced between ~3 and 6 days after initial infection and did not increase the expression of well-characterized interferon-stimulated genes (ISGs). Indeed, increased MyD88 expression downregulated the expression of almost all ISGs examined. UL88 overexpression suppressed IL-1β-induced NF-κB activation within a cell. UL88 also suppressed virus-induced translocation of NF-κB to the nucleus of uninfected neighboring cells in an infected monolayer. Furthermore, UL88 overexpression was required for effective HCMV spread following transfer of the virus from monocytes to a fibroblast monolayer. These data indicate that UL88 is a novel antagonist of the immune response that acts to enhance the natural spread of HCMV by targeting MyD88 and provides vital insight into the innate immune responses that can control HCMV spread.IMPORTANCEThe significant role of many viral genes encoded by HCMV that are not essential for replication in cell culture is often overlooked. Our study reveals the importance of UL88 for regulating the innate immune response by showing evidence for interaction with and downregulation of MyD88 protein. The UL88-dependent regulation of MyD88 is physiologically relevant, as infection is enhanced in the absence of MyD88, and spread from myeloid cells to fibroblasts is blunted in the absence of UL88. These results highlight yet another important interaction between HCMV and the immune system.

Indexed as

CytomegalovirusCytomegalovirus InfectionsImmunity, InnateMyeloid Differentiation Factor 88Viral ProteinsFibroblastsHumansInterleukin-1betaNF-kappa BProteolysisSignal TransductionInterleukin-1betaMYD88 protein, humanMyeloid Differentiation Factor 88NF-kappa BViral ProteinsHCMVimmune activationMyD88UL88

Identifiers

PMID40638072
PMCPMC12363176

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.